Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine

BackgroundThe goal of this prospective study was to compare the value of both conventional MRI and O-(2-F-18-fluoroethyl)-L-tyrosine (FET) PET for response evaluation in glioblastoma patients treated with bevacizumab plus lomustine (BEV/LOM) at first progression.MethodsAfter chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75years; MGMT promoter unmethylated, 81%) were treated with BEV/LOM. Contrast-enhanced MRI and FET-PET scans were performed at baseline and after 8-10weeks. We obtained FET metabolic tumor volumes (MTV) and tumor/brain ratios. Threshold values of FET-PET parameters for treatment response were established by ROC analyses using the post-progression overall survival (OS) />9months as the reference. MRI response assessment was based on RANO criteria. The predictive ability of FET-PET thresholds and MRI changes on early response assessment was evaluated subsequently concerning OS using uni- and multivariate survival estimates.ResultsEarly treatment response as assessed by RANO criteria was not predictive for an OS>9months (P=0.203), whereas relative reductions of all FET-PET parameters significantly predicted an OS>9months (P<0.05). The absolute MTV at follow-up enabled the most significant OS prediction (sensitivity, 85%; specificity, 88%; P=0.001). Patients with an absolute MTV below 5ml at follow-up survived significantly longer (12 vs. 6months, P<0.001), whereas early responders defined by RANO criteria lived only insignificantly longer (9 vs. 6months; P=0.072). The absolute MTV at follow-up remained significant in the multivariate survival analysis (P=0.006).ConclusionsFET-PET appears to be useful for identifying responders to BEV/LOM early after treatment initiation.